Skip to main content


Exciting and important news in the diabetes sphere from the biggest diabetes conferences around the world. 

The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.
Our trip to Berlin brought new insights on implantable GLP-1, the latest in CGM and the artificial pancreas, and debates on early insulin therapy.
The 2012 Diabetes Technology Meeting provides new insights into the artificial pancreas and the latest thinking on regulation from the FDA.
The artificial pancreas in peoples’ homes at the Annual Technologies & Treatments for Diabetes Meeting in Paris.
In late June, diaTribe sent our team to Chicago to attend the 67th Annual Scientific Sessions of the American Diabetes Association.
Click to learn exciting news on the artificial pancreas, faster insulins, and the results of the much-anticipated ORIGIN trial.
Can more type 2 therapies be used for type 1 diabetes?
The FDA impresses us at The Diabetes Mine Innovation Summit. Plus, sleek new software for downloading data to the cloud.
A game-changing therapy for type 2 diabetes? Plus, the latest on predictive low glucose suspend, faster insulin, and a better Bydureon.
What do Michelle Obama, soda, and cities have in common? Our top five patient takeaways from PHA this year.
Five key insights from April’s big-deal artificial pancreas meeting in Washington, DC.
The evolving field of type 1 diabetes and how research should improve to get closer to finding a cure.
What it felt like to forget about diabetes for a week.
At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia.
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
Twitter summary: dT presents at @US_FDA on interim results for CVOT trials in #diabetes & why we can’t delay innovation In 2008, the FDA mandated that companies...
Will Medicare cover CGM? Will the FDA regulate meters? Experts meet in D.C. to discuss...
This year at ADA, the science was exciting as always, but what really made us happy was the deep focus on patient perspectives.
Advances for type 2 diabetes at The American Diabetes Association 74th Scientific Sessions